Literature DB >> 21320828

Stereotactic radiotherapy: an emerging treatment for spinal metastases.

Max Dahele1, Michael G Fehlings, Arjun Sahgal.   

Abstract

AIM: The purpose of this concise update is to describe the emerging treatment of stereotactic body radiotherapy (SBRT) for spinal metastases. RATIONALE: Spinal metastases are common and can present complex clinical challenges that conventional treatment cannot always meet satisfactorily. Examples include a history of prior irradiation at the same site or radio-resistant tumor histology. Stereotactic body radiotherapy makes it possible to deliver high doses of radiation with the aim of improving tumor control and palliation. It is increasingly being offered to selected patients including those requiring re-irradiation and post-operative treatment.
CONCLUSION: It is important that specialists managing patients with spinal metastases are aware of the potential advantages of SBRT and how this can complement and extend existing treatment approaches, including spinal decompression and stabilization.

Entities:  

Mesh:

Year:  2011        PMID: 21320828     DOI: 10.1017/s0317167100011410

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  3 in total

Review 1.  Image guidance in spine tumor surgery.

Authors:  Patrick D Kelly; Scott L Zuckerman; Yoshiya Yamada; Eric Lis; Mark H Bilsky; Ilya Laufer; Ori Barzilai
Journal:  Neurosurg Rev       Date:  2019-06-01       Impact factor: 3.042

2.  Spinal cord biological safety of image-guided radiation therapy versus conventional radiation therapy.

Authors:  Wanlong Xu; Hao Liu; Ruozheng Wang; Jingping Bai
Journal:  Neural Regen Res       Date:  2012-12-15       Impact factor: 5.135

Review 3.  Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation.

Authors:  Michael Huo; Arjun Sahgal; David Pryor; Kristin Redmond; Simon Lo; Matthew Foote
Journal:  Surg Neurol Int       Date:  2017-02-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.